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56 Poster Session-Ievaluation pre-BMT predicting outcomes post-BMT.We retrospec-
tively analyzed 204 consecutive first adult ($18 years) autologous (n
5 108) or allogeneic (n 5 96) BMT pts treated from 7/05 to 5/08 to
analyze BMT outcomes in relation to a comprehensive psychosocial
evaluation. 200/204 (98%) had a psychosocial inventory assessment
collected by in-person interview with a BMT social worker during
their routine pre-BMT evaluation. The psychosocial inventory had
questions regarding employment, marital status, education, financial
concerns, transportation and local lodging needs, degree of under-
standingofdiagnosis and treatment, tobacco, alcohol anddruguse, im-
portance of and comfort with religious beliefs, and personal or family
suicidal ideation or attempt. Median age was 53 years (range 18–74),
62% were male, 93% were White, diagnoses included leukemia (n5
73), lymphoma (n 5 71), myeloma (n 5 36), hematologic disorders
(n 5 17), and solid tumors (n 5 3), donors were autologous (n 5
106), related (n 5 41), or unrelated (n 5 53). Median follow-up in
the survivors was 1.1 years (range 0.1–3). By univariate analysis, signif-
icant predictors of decreased 1-year overall survival (OS) in allogeneic
BMT pts were KPS # 80 (47% vs. 75%, p 5 0.003), marital status
(married 39% vs. never married 69% vs divorced 90%, p 5 0.016),
not living alone pre-BMT(48%vs. 100%,p5 0.012) and smoking sta-
tus (ever 42%vs. never 67%, p5 0.07).Marital statuswas significantly
related to agewithmedian 53 vs. 36.5 vs. 46.7 years ofmarried vs. never
married vs. divorced pts. By univariate analysis, the only significant
predictor of decreased 1-year OS in autologous BMT pts was living
.30 minute drive from the BMT center and needed local lodging
(72% vs. 93%, p5 0.006). For allogeneic BMT, multivariate analysis
demonstratedKPS#80 (RR54.6, 95%CI1.4–15,p50.01),married
compared to divorced (RR5 5.9, 95% CI 0.8–44, p5 0.08) and for-
mer/current smokers (RR5 1.8, 95%CI 0.9–3.4, p5 0.08) had an in-
creased risk of death. Substituting age for marital status in the model
yielded only KPS as a significant factor. Some psychosocial factors
may be related to patient and disease related characteristics which
may yield selection bias in the decision to transplant or not. Further
analyses of psychosocial factors in larger, more homogeneous patient
populations may help clarify risk subgroups.148
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Introduction: Viral infections are a common cause of complica-
tion after hemopoietic stem cell transplantation (HSCT).Data on vi-
ral co-infection followingHSCT in pediatrics is limited.We studied
the incidence, clinical characteristics and outcome of cytomegalovi-
rus (CMV), adenovirus (ADV), BK virus (BKV) and JC virus (JCV)
co-infection in pediatric recipients of HSCT.
Methods: We performed quantitative PCR of ADV, BKV and
JCV in 191 blood samples from 73 pediatric patients, initially tested
for quantitative CMVPCR followingHSCT.We retrospectively re-
viewed medical records among these patients.
Results: Viral DNA was presence in 55 (75.3%) of 73 patients.
The incidence of viral detection was highest for BKV, followed by
CMV, ADV and JCV (24, 16, 8 and 0.4 cases per 1000 person-weeks,
respectively). The median plasma CMV, ADV and BKV viral load
(copies/ml) was 8,350, 8,380 and 77.2, respectively. Viral co-
infection was common and occurred in 27 (37%) of 73 patients, of
whom 22 and 5 were dual and triple viruses, respectively. The major
viral co-infections were CMVplus BKV, ADVplus BKV, and CMV,
ADVplus BKV ((12 (16.4%), 6(8.2%) and 5(6.8%) of 73 patients, re-
spectively). A peak ADVviral loadwas significantly higher in patients
who had ADV viral co-infection as compared to ADV mono-
infection (p 5 0.017), whereas a peak CMV viral load did not differ
between patients with CMV viral co-infection and CMV mono-
infection (p 5 0.218). In contrast, a peak BKV viral load was signif-
icantly higher in patients who had BKV mono viral infection than
BKV viral co-infection (p 5 0.003). From multivariate analysis,
type of HSCT was significantly associated with viral co-infection(OR 4.2 (95%CI 1.6–10.7, p 5 0.003) and allogeneic HSCT from
unrelated donor was the most predominant. Symptomatic infection
occurred in 25 patients, of whom 15 (55.6%) had viral co-infection.
Hemorrhagic cystitis was noted to be the only presentation in 15
(60%) whereas multi-organ dysfunction was noted in 7 (28%) of
25 patients. Among patients withmulti-organ dysfunction, peak viral
load of CMV, ADV and BKV was higher, more types of virus
co-reactivation were detected and 5 of them had died.
Conclusion: In pediatric HSCT, symptomatic viral co-infection
is common.Patients who succumbed with the more types of virus
co-reactivation had higher probability of having multiple-organ dys-
functions. Routine ADV and BKVPCRmonitoring is encouraged in
pediatric recipients of allogeneic HSCT.149
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Background:Althoughperipheral blood stemcell (PBSC)donation
has beenconsidered safe and less stressful, certain fetal or life-threaten-
ing accidents have been reported among donors. Since the JapanMar-
row Donor Program requires the confirmation of the safety and the
risk ofPBSCdonation at familydonorsprior toapplying this technique
for volunteer donors, the JapanSociety forHematopoieticCellTrans-
plantation (JSHCT) has established a nation-wide consecutive pre-
registration system for PBSC family donors.
Methods: The JSHCT mandates the registration of every PBSC
family donor at the donor registration center then, issues donor iden-
tificationnumber toeachdonor.Thesociety alsorequires everyharvest
center to observe the JSHCTstandards for donor eligibility and to no-
tify it of any severe adverse events, the results of a day30 check and of
the annual health check for five years. The cost for the day 30 check
is covered by the national health insurance in Japan and the cost of
the annual health check for 5 years is covered by the JSHCT with
the support of two G-CSF producing and (or) marketing companies.
To gather information on bone marrow family donors, the JSHCT
collaboratedwith theEuropeanBloodandMarrowTransplantGroup.
Findings: Our prospective survey revealed that certain acute se-
vere adverse events occurred even in donors who had been confirmed
to be healthy. However, no mortality nor morbidity cases were
found, suggesting that the pre-registration system with its standards
for donor eligibility has been effective in preventing real life-threat-
ening adverse events. The results of the annual health check for 5
years showed that the incidence of hematological malignancies
among PBSC donors was not high compared with that among retro-
spectively surveyed bone marrow donors.
Interpretation:The donor pre-registration system that sets strict
standards for donor eligibility is useful to know the real figures on
PBSC donors and to assure donor safety. Such a system should be
applied to all hematopoietic stem cell donors.LEUKEMIA
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Infusion of donor derived cytomegalovirus (CMV), adenovirus (Ad)
and Epstein-Barr-Virus (EBV) specific cytotoxic T lymphocytes
(CTLs) appears to safely protect against viral infections post hemato-
poietic stem cell transplantation (HSCT).HSCT for pre-B acute lym-
phoblastic leukemia (B-ALL) is associated with a high rate of relapse.
We hypothesized that monoculture-derived multivirus specific CTLs
can be engineered to express chimeric antigen receptors (CAR) specific
